|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CACNG8 |
Gene summary for CACNG8 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CACNG8 | Gene ID | 59283 |
| Gene name | calcium voltage-gated channel auxiliary subunit gamma 8 | |
| Gene Alias | CACNG8 | |
| Cytomap | 19q13.42 | |
| Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q8WXS5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 59283 | CACNG8 | HCC2_Meng | Human | Liver | HCC | 2.53e-06 | 1.45e-01 | 0.0107 |
| 59283 | CACNG8 | HCC1 | Human | Liver | HCC | 1.19e-14 | 1.38e+00 | 0.5336 |
| 59283 | CACNG8 | HCC2 | Human | Liver | HCC | 6.81e-31 | 2.29e+00 | 0.5341 |
| 59283 | CACNG8 | HCC5 | Human | Liver | HCC | 4.86e-36 | 1.90e+00 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007259422 | Liver | HCC | establishment of protein localization to organelle | 299/7958 | 422/18723 | 1.06e-32 | 6.10e-30 | 299 |
| GO:000703421 | Liver | HCC | vacuolar transport | 108/7958 | 157/18723 | 2.22e-11 | 8.69e-10 | 108 |
| GO:000704121 | Liver | HCC | lysosomal transport | 76/7958 | 114/18723 | 1.56e-07 | 2.88e-06 | 76 |
| GO:00315031 | Liver | HCC | protein-containing complex localization | 129/7958 | 220/18723 | 9.38e-07 | 1.42e-05 | 129 |
| GO:007266521 | Liver | HCC | protein localization to vacuole | 48/7958 | 67/18723 | 1.27e-06 | 1.85e-05 | 48 |
| GO:00726662 | Liver | HCC | establishment of protein localization to vacuole | 35/7958 | 49/18723 | 3.90e-05 | 3.85e-04 | 35 |
| GO:004311221 | Liver | HCC | receptor metabolic process | 96/7958 | 166/18723 | 4.69e-05 | 4.50e-04 | 96 |
| GO:00614621 | Liver | HCC | protein localization to lysosome | 33/7958 | 46/18723 | 5.63e-05 | 5.26e-04 | 33 |
| GO:000689821 | Liver | HCC | receptor-mediated endocytosis | 134/7958 | 244/18723 | 5.73e-05 | 5.31e-04 | 134 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CACNG8 | SNV | Missense_Mutation | novel | c.238G>A | p.Gly80Ser | p.G80S | Q8WXS5 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-A2-A0CK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | CR |
| CACNG8 | SNV | Missense_Mutation | c.424N>T | p.Gly142Trp | p.G142W | Q8WXS5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | |
| CACNG8 | SNV | Missense_Mutation | novel | c.618N>G | p.Phe206Leu | p.F206L | Q8WXS5 | protein_coding | deleterious(0.02) | probably_damaging(0.979) | TCGA-EW-A3E8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
| CACNG8 | SNV | Missense_Mutation | c.223N>C | p.Glu75Gln | p.E75Q | Q8WXS5 | protein_coding | tolerated(0.23) | benign(0.288) | TCGA-DG-A2KL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| CACNG8 | SNV | Missense_Mutation | novel | c.293N>T | p.Arg98Ile | p.R98I | Q8WXS5 | protein_coding | deleterious(0) | benign(0.038) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| CACNG8 | SNV | Missense_Mutation | c.691A>G | p.Ser231Gly | p.S231G | Q8WXS5 | protein_coding | deleterious(0.02) | benign(0.121) | TCGA-QG-A5YW-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | capecitabine | CR | |
| CACNG8 | SNV | Missense_Mutation | novel | c.340G>T | p.Asp114Tyr | p.D114Y | Q8WXS5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CACNG8 | SNV | Missense_Mutation | novel | c.353N>T | p.Ala118Val | p.A118V | Q8WXS5 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CACNG8 | SNV | Missense_Mutation | novel | c.361C>A | p.Leu121Ile | p.L121I | Q8WXS5 | protein_coding | tolerated(0.2) | probably_damaging(0.99) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CACNG8 | SNV | Missense_Mutation | novel | c.592N>C | p.Asn198His | p.N198H | Q8WXS5 | protein_coding | tolerated(0.25) | possibly_damaging(0.814) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |